Q1 outperformance was fuelled by the stockpiling of drugs, particularly for chronic and generic medicines. While these pantry-loading benefits, mainly in the consumer healthcare segment, should fade away in Q2, robust demand for speciality care drugs, especially Dupixent, would ensure that FY20 financial targets are met. COVID-19-related opportunities – Sanofi is working on vaccines, diagnostics as well as short-term relief drugs – makes the French firm even more attractive and th
